BPC-157 (Body Protection Compound-157) is a 15-amino acid gastric pentadecapeptide investigated for its interactions with angiogenesis, nitric oxide signaling, and growth factor receptor pathways
The other just submitted for FDA approval first
These are dietary supplements rather than research peptides, and they're readily available without the regulatory complexity of injectable peptides
Tirzepatide has been approved for T2D management - the mean HbA1c reduction in SURPASS programme ranged between 1.9 and 2.6% across the trials and 4069% of participants achieved 10% WL with the higher doses (10 and 15 mg), despite that there was no additional support for lifestyle intervention [16, 43]
Life Sciences, 231 , 116584
Dihexa exhibits procognitive activity